Title: Eradication therapy may decrease the risk of immune thrombocytopenia after
Helicobacter pylori infection: A retrospective cohort study in Taiwan
Version: 0 Date: 02 Dec 2022
Reviewer's report:
I have to express my appreciation for the idea which this paper based on
However I have some inquiries
1. The title for me not attractive I think you have to modulate it to be more short and attractive
2. You had a criteria for thrombocytopenia of less than 1000000 however we have a spectrum
of patients from 100 to 150 thousands which may be considered an evolving immune patients,
what about them in yours.
3. Presence a significant differences according to age and CCI  is a considerable weakness for
the results.
4. You stated that there is anemia in comorbidities but in the outcome you excluded any
erythrocytes disorders, explain please.
5. In the results where are results for plts nombers and at what point of time as from the study
design it is not clear the timeline for the patients followup.
6. Did you excluded the antiphospholipid antibodies?
7. In the discussion you tried to explain why females had a lower risk to develop
thrombocytopenia but it is still unclear.
Title: Eradication therapy may decrease the risk of immune thrombocytopenia after
Helicobacter pylori infection: A retrospective cohort study in Taiwan
Version: 0 Date: 02 Dec 2022
Reviewer's report:
I have to express my appreciation for the idea which this paper based on
However I have some inquiries
1. The title for me not attractive I think you have to modulate it to be more short and attractive
2. You had a criteria for thrombocytopenia of less than 1000000 however we have a spectrum
of patients from 100 to 150 thousands which may be considered an evolving immune patients,
what about them in yours.
3. Presence a significant differences according to age and CCI  is a considerable weakness for
the results.
4. You stated that there is anemia in comorbidities but in the outcome you excluded any
erythrocytes disorders, explain please.
5. In the results where are results for plts nombers and at what point of time as from the study
design it is not clear the timeline for the patients followup.
6. Did you excluded the antiphospholipid antibodies?
7. In the discussion you tried to explain why females had a lower risk to develop
thrombocytopenia but it is still unclear.
Please review this paper.
user
Title: Eradication therapy may decrease the risk of immune thrombocytopenia after
Helicobacter pylori infection: A retrospective cohort study in Taiwan
Version: 0 Date: 02 Dec 2022
Reviewer's report:
I have to express my appreciation for the idea which this paper based on
However I have some inquiries
1. The title for me not attractive I think you have to modulate it to be more short and attractive
2. You had a criteria for thrombocytopenia of less than 1000000 however we have a spectrum
of patients from 100 to 150 thousands which may be considered an evolving immune patients,
what about them in yours.
3. Presence a significant differences according to age and CCI  is a considerable weakness for
the results.
4. You stated that there is anemia in comorbidities but in the outcome you excluded any
erythrocytes disorders, explain please.
5. In the results where are results for plts nombers and at what point of time as from the study
design it is not clear the timeline for the patients followup.
6. Did you excluded the antiphospholipid antibodies?
7. In the discussion you tried to explain why females had a lower risk to develop
thrombocytopenia but it is still unclear.
assistant